SCHEMBL4126476

SCHEMBL4126476

CC(C)N(C(=O)Nc1c[nH]nc1-c1nc2cc(F)c(OCCCN(C)C)cc2[nH]1)C(C)C

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ITK Q08881 2/20 0.43
SYK P43405 1/20 0.43
CHEK2 O96017 2/20 0.37
ATM Q13315 5/20 0.33
HRH4 Q9H3N8 1/20 0.33
ROCK2 O75116 4/20 0.32
ROCK1 Q13464 1/20 0.32
CDC42BPA Q5VT25 1/20 0.32
KDR P35968 2/20 0.32
CHEK1 O14757 1/20 0.32
SRPK2 P78362 1/20 0.32
SRPK1 Q96SB4 1/20 0.32
CACNA1H O95180 1/20 0.31
MET P08581 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4126777 0.94 SYK (0.42) ITKSYKCHEK2ATMHRH4
SCHEMBL4002962 0.91 SYK (0.43) ITKSYKCHEK2ATMHRH4
SCHEMBL4121801 0.89 SYK (0.53) ITKSYKCHEK2ATMHRH4
SCHEMBL4124795 0.88 SYK (0.38) ITKSYKCHEK2ATMHRH4
SCHEMBL4122016 0.88 SYK (0.47) ITKSYKCHEK2ATMHRH4
SCHEMBL4122351 0.87 SYK (0.37) ITKSYKCHEK2ATMHRH4
SCHEMBL4121774 0.86 SYK (0.41) ITKSYKCHEK2ATMHRH4
SCHEMBL4122246 0.85 ATM (0.38) ITKSYKCHEK2ATMKDR
SCHEMBL3935250 0.85 SYK (0.38) ITKSYKCHEK2ATMHRH4
Trifluoroacetic Acid SCHEMBL4134146 0.85 SYK (0.49) ITKSYKCHEK2ATMHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2041119-B1 PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF AVENTIS PHARMA SA (FR) 2017-05-10 EP claimed
US-9126969-B2 Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2015-09-08 US claimed
US-20090197866-A1 PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2009-08-06 US claimed
EP-2041119-B1 PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF AVENTIS PHARMA SA (FR) 2017-05-10 EP disclosed
US-9126969-B2 Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2015-09-08 US disclosed
US-9126969-B2 Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2015-09-08 US disclosed
US-9126969-B2 Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2015-09-08 US disclosed
US-20090197866-A1 PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2009-08-06 US disclosed
US-20090197866-A1 PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197866-A1 PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF RB1, CCNI, CDK2 ITK 1817/4885SYK 392/4885CHEK2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.